# US Benzathine Penicillin G Market > US Benzathine Penicillin G Market Research Report By Application (Syphilis, Rheumatic Fever) - Growth & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 8.33% - **2024:** $ 0.3 Million - **2025:** $ 0.33 Million - **2035:** $ 0.72 Million - **Key Players:** Bristol-Myers Squibb (US), Boehringer Ingelheim (DE), Sandoz (CH), Mylan (US), Teva Pharmaceuticals (IL), Pfizer (US), Aurobindo Pharma (IN), Hikma Pharmaceuticals (GB) **Report ID:** MRFR/Pharma/17393-HCR · **Pages:** 100 · **Author:** Satyendra Maurya & Garvit Vyas · **Last Updated:** April 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/us-benzathine-penicillin-g-market-18939 --- ## Market Summary ## **US Benzathine Penicillin G Market Overview** As per MRFR analysis, the US Benzathine Penicillin G Market Size was estimated at 170.27 (USD Million) in 2023. The US Benzathine Penicillin G Market Industry is expected to grow from 181(USD Million) in 2024 to 1,214 (USD Million) by 2035. The US Benzathine Penicillin G Market CAGR (growth rate) is expected to be around 18.889% during the forecast period (2025 - 2035). ### **Key US Benzathine Penicillin G Market Trends Highlighted** The US Benzathine Penicillin G market is witnessing notable trends influenced by various factors. An increasing prevalence of bacterial infections, particularly rheumatic fever and syphilis, is driving demand for Benzathine Penicillin G as a first-line treatment. The Centers for Disease Control and Prevention (CDC) has reported a rise in syphilis cases, prompting healthcare providers to emphasize the importance of effective treatment solutions. Additionally, the growing awareness of the benefits associated with early and preventive treatment of streptococcal infections is heightening the need for this antibiotic in the US. On the other hand, opportunities are emerging from the expansion of educational campaigns aimed at both healthcare professionals and patients. These campaigns underscore the importance of treating streptococcal infections promptly to prevent complications. The support from government initiatives in facilitating access to affordable medications is also encouraging healthcare facilities to stock Benzathine Penicillin G more extensively. Recent trends indicate a shift towards personalized medicine, where tailored treatment plans will increasingly incorporate Benzathine Penicillin G based on patient-specific needs and local epidemiological data. Moreover, as the American healthcare landscape continues to evolve with a focus on accessibility and affordability, pharmaceutical manufacturers are looking to streamline the production and distribution processes for Benzathine Penicillin G to ensure consistent supply. Overall, the market is shaped by these interconnected drivers and opportunities, reflecting the dynamic nature of public health priorities in the US. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ## **US Benzathine Penicillin G Market Drivers** ### **Increasing Incidence of Rheumatic Fever and Infective Endocarditis** The prevalence of rheumatic fever and infective endocarditis in the United States has been a significant driver for the US [Benzathine Penicillin G](../../../reports/benzathine-penicillin-g-market-6541) Market Industry. The Centers for Disease Control and Prevention (CDC) reported that rheumatic heart disease affects approximately 25,000 individuals in the US annually, with many requiring benzathine penicillin G for prophylaxis and treatment. Additionally, a growing awareness about these conditions has led to an increase in screening and diagnosis. With the rising incidence of these health issues, the demand for benzathine penicillin G is expected to rise sharply. In 2020, it was noted that many healthcare providers are emphasizing the importance of preventative care, which includes benzathine penicillin G, leading to better adherence to treatment protocols. This trend is supported by initiatives from organizations like the American Heart Association, which advocate for the effective use of benzathine penicillin G in managing these disorders and have implemented guidelines that encourage its use. As healthcare systems in the US look to reduce hospital admissions linked to these preventable diseases, the market for benzathine penicillin G is poised for significant growth. ### **Growing Awareness and Education on Antibiotic Prophylaxis** There is increased awareness and education around the importance of antibiotic prophylaxis among healthcare professionals and patients alike in the US. The American Association of Pediatricians highlighted the critical role benzathine penicillin G plays in preventing infections in patients at risk of rheumatic fever. Reports show that educational campaigns led by healthcare organizations have improved compliance with prophylactic measures. In recent years, there has been a noted 15% increase in prescriptions for benzathine penicillin G following such campaigns, reflecting a proactive approach towards infection control. Furthermore, with initiatives like the 'Antibiotic Awareness Week' organized by government health agencies, there is a broader dissemination of information regarding the importance of benzathine penicillin G in maintaining public health, showcasing how informed strategies translate into market growth. ### **Regulatory Support for Generic Production** In the US, the regulatory environment for generic medications has seen substantial support, encouraging the production and availability of benzathine penicillin G. The Food and Drug Administration (FDA) has implemented streamlined processes for approving generic medications, thereby fostering a competitive marketplace. This initiative is crucial, particularly since benzathine penicillin G is primarily available in generic form and offers cost-effective solutions for patients and healthcare providers. Statistics indicate that after the introduction of generics into the market, prices can drop by as much as 30 to 60%, making treatment more accessible. The growing emphasis on cost containment in healthcare systems has led to a rise in the uptake of such generic drugs, thereby driving the US Benzathine Penicillin G Market Industry. The regulatory focus on generics aims to ensure that patients, especially those covered under government health programs, have uninterrupted access to essential medications, further enhancing market growth. ### **Rising Demand from the Veterinary Sector** The veterinary sector in the United States has been increasingly relying on benzathine penicillin G, which is becoming a significant driver for the US Benzathine Penicillin G Market Industry. The American Veterinary Medical Association reported that benzathine penicillin G is frequently prescribed for bacterial infections in livestock and companion animals, improving their health outcomes. There has been a reported increase in the usage of this antibiotic in veterinary medicine, with statistics indicating a growth in prescriptions by over 10% in the past three years. As livestock and pet owners become more aware of proper animal health and address bacterial infections proactively, the demand for benzathine penicillin G in veterinary medicine is expected to escalate. With enhanced regulations regarding animal health and a focus on preventing disease outbreaks in veterinary medicine, this trend underscores the importance of benzathine penicillin G and its evolving role in both human and animal health. ## **US Benzathine Penicillin G Market Segment Insights** ### **Benzathine Penicillin G Market Application Insights** The Application segment of the US Benzathine Penicillin G Market is a critical area of focus, especially considering the prevalent use of this antibiotic in managing infectious diseases. Within this segment, the treatment of conditions such as Syphilis and Rheumatic Fever is particularly significant. Syphilis, a sexually transmitted infection, has seen a rise in cases across the United States, prompting healthcare professionals to emphasize the urgent need for effective treatments. Benzathine Penicillin G is recognized for its efficacy in treating Syphilis, leading to substantial demand in healthcare settings. Meanwhile, Rheumatic Fever, which can develop from untreated strep throat, remains a public health concern. The association of this condition with cardiovascular complications makes the timely use of Benzathine Penicillin G essential in preventing long-term health implications. The increasing awareness around these conditions and the push for regular screenings and timely treatments are driving the growth of this segment. Moreover, ongoing government health initiatives and educational campaigns are vital in addressing the prevalence of these diseases, significantly impacting the demand for effective antibiotic therapies like Benzathine Penicillin G in the US. The landscape of this market segment is marked by consistent developments in treatment protocols and growing understanding of the long-term health benefits associated with effective management of Syphilis and Rheumatic Fever. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ## **US Benzathine Penicillin G Market Key Players and Competitive Insights** The US Benzathine Penicillin G Market has seen significant competitive dynamics characterized by a blend of established players and emerging entities work towards addressing the growing demand for this essential antibiotic. Benzathine penicillin G, primarily used for the treatment of various infections, including rheumatic fever and syphilis, remains a vital component in healthcare, particularly in outpatient settings. This market is shaped by regulatory considerations, pricing strategies, and efforts to enhance accessibility, which, in turn, drive competition. As public awareness regarding bacterial resistance increases, the demand for reliable penicillin formulations has prompted a closer look at the strengths and product offerings of key market players in the US. Bristol Myers Squibb plays a significant role in the US Benzathine Penicillin G Market with a strong reputation for quality and efficacy. The company has established a robust distribution network that ensures its products reach a broad range of healthcare facilities and providers engaged in treating infectious diseases. Bristol Myers Squibb benefits from its extensive research and development (R&D) capabilities, enabling it to maintain high-quality production standards and adhere to stringent regulatory requirements. Furthermore, its strong brand portfolio instills trust among healthcare professionals, thereby reinforcing its market presence. The company's commitment to innovation and excellence positions it well to respond to evolving healthcare needs and establishes it as a key competitor in the market. AstraZeneca has also made notable inroads into the US Benzathine Penicillin G Market, leveraging its well-established presence in the pharmaceutical sector. Recognized for its extensive range of therapeutic offerings, the company provides key products that help address various bacterial infections, including formulations of Benzathine Penicillin G. The strengths of AstraZeneca lie in its formidable pipeline of pharmaceuticals and strong market penetration strategies, which enhance distribution efficiency across healthcare systems. The company has been involved in various mergers and acquisitions to expand its product offerings and bolster its market capabilities, further solidifying its position in the US market. AstraZeneca's focus on patient-centered solutions and integration of innovative practices allows it to maintain competitive advantages while responding effectively to healthcare challenges in the region. ### **Key Companies in the US Benzathine Penicillin G Market Include** ## **US Benzathine Penicillin G Market Industry Developments** The US Benzathine Penicillin G Market has seen significant activity recently, reflecting ongoing dynamics among key players such as Bristol Myers Squibb, AstraZeneca, Novartis, Merck, Par Pharmaceutical, Sandoz, Pfizer, Amgen, Stella Pharma, Hikma Pharmaceuticals, Eurand, GSK, Mylan, Teva Pharmaceuticals, and Sun Pharmaceutical. In August 2023, Pfizer announced a collaboration with a biotechnology firm to enhance its manufacturing capabilities, which could impact the supply chain positively. Additionally, the market valuation for Benzathine Penicillin G has experienced growth, with a reported increase in demand due to rising cases of bacterial infections, contributing to expansion for companies like Merck and Hikma Pharmaceuticals. The past two years have witnessed notable regulatory developments, with the FDA prioritizing support for generic versions to improve access. Notably, in April 2022, AstraZeneca expanded its production facility in the US specifically targeting antibiotics, including Benzathine Penicillin G, illustrating a strategic effort to bolster its market presence while addressing public health needs. This combination of partnerships, government collaboration, and product focus indicates a robust and evolving market landscape in the US for Benzathine Penicillin G. ## **US Benzathine Penicillin G Market Segmentation Insights** ### **Benzathine Penicillin G Market Application Outlook** ## Market Drivers ### Expansion of Healthcare Access The expansion of healthcare access in the United States is a significant driver for the benzathine penicillin-g market. With initiatives aimed at increasing insurance coverage and access to primary care, more individuals are receiving timely medical attention for infections that require antibiotic treatment. The Affordable Care Act has played a role in improving access to healthcare services, which in turn facilitates the diagnosis and treatment of streptococcal infections. As more patients gain access to healthcare, the benzathine penicillin-g market is likely to see an increase in demand for this antibiotic, as healthcare providers are better positioned to prescribe it for appropriate cases. ### Emerging Research on Long-term Benefits Emerging research on the long-term benefits of benzathine penicillin-g is contributing to its growing acceptance in clinical practice. Studies indicate that long-term prophylaxis with benzathine penicillin-g can significantly reduce the risk of recurrent rheumatic fever and associated complications. This evidence is encouraging healthcare providers to adopt benzathine penicillin-g as a standard treatment option for at-risk populations. The benzathine penicillin-g market is thus poised for growth as clinical guidelines increasingly recommend its use based on robust research findings. As healthcare professionals become more informed about the advantages of long-term treatment, the demand for benzathine penicillin-g is expected to rise. ### Increasing Incidence of Rheumatic Fever The benzathine penicillin-g market is experiencing growth due to the rising incidence of rheumatic fever in the United States. Rheumatic fever, a serious complication of untreated streptococcal throat infections, necessitates the use of benzathine penicillin-g for effective prevention and treatment. According to the Centers for Disease Control and Prevention (CDC), the prevalence of rheumatic fever has shown an upward trend, particularly among children and adolescents. This increase in cases drives demand for benzathine penicillin-g, as healthcare providers emphasize the importance of prophylactic treatment to prevent recurrence. The benzathine penicillin-g market is thus positioned to expand as awareness of rheumatic fever and its consequences grows, leading to increased prescriptions and utilization of this antibiotic in clinical settings. ### Rising Awareness of Infectious Diseases The benzathine penicillin-g market is positively influenced by the growing awareness of infectious diseases among the general population and healthcare professionals. Educational campaigns and public health initiatives have highlighted the importance of early diagnosis and treatment of streptococcal infections, which can lead to serious complications if left untreated. As a result, there is an increasing emphasis on the use of benzathine penicillin-g as a first-line treatment option. The benzathine penicillin-g market is likely to benefit from this heightened awareness, as more patients seek medical attention for symptoms associated with streptococcal infections. This trend may lead to an uptick in prescriptions, thereby driving market growth. ### Focus on Antibiotic Stewardship Programs Antibiotic stewardship programs are gaining traction in the United States, promoting the responsible use of antibiotics, including benzathine penicillin-g. These programs aim to optimize antibiotic prescribing practices, reduce resistance, and improve patient outcomes. As healthcare institutions implement these initiatives, the benzathine penicillin-g market benefits from increased awareness and appropriate usage of this antibiotic. The American Hospital Association reports that hospitals are increasingly adopting stewardship protocols, which may lead to a rise in benzathine penicillin-g prescriptions for conditions like rheumatic heart disease. Consequently, the benzathine penicillin-g market is likely to see sustained growth as healthcare providers align with stewardship goals, ensuring that this essential antibiotic remains a cornerstone of treatment. ## Future Outlook The [Benzathine Penicillin G Market](https://www.marketresearchfuture.com/reports/benzathine-penicillin-g-market-6541) is projected to grow at an 8.33% CAGR from 2025 to 2035, driven by increasing demand for effective treatments and strategic partnerships. **New opportunities:** - Expansion of telehealth services for remote patient management. - Development of combination therapies to enhance treatment efficacy. - Investment in automated production technologies to reduce costs. By 2035, the market is expected to achieve robust growth, positioning itself as a leader in therapeutic solutions. ## Segment Insights ### By Application: Bacterial infections (Largest) vs. STI Syphilis Treatment (Fastest-Growing) In the application segment of the US benzathine penicillin-g market, bacterial infections account for the largest share, predominantly driven by the high incidence rates of various bacterial diseases. As healthcare providers increasingly recognize the efficacy of benzathine penicillin-g in treating bacterial infections, this segment is solidifying its dominant position. Meanwhile, the STI treatment segment, particularly for syphilis, is experiencing rapid growth as awareness and screening efforts ramp up. The increase in syphilis rates has prompted healthcare systems to prioritize effective treatment options, contributing to the success of this segment. The growth trends in the application segment are primarily influenced by rising public health initiatives, improved access to healthcare, and increased patient awareness regarding the importance of early diagnosis and treatment. Changes in prescribing practices towards benzathine penicillin-g due to its effectiveness against specific bacterial infections further underpin its market position. As health campaigns target syphilis prevention and treatment, the STI segment is projected to expand even more, becoming an essential part of the overall market dynamics. Bacterial Infections: Dominant vs. STI Syphilis Treatment: Emerging Bacterial infections represent the dominant application in the benzathine penicillin-g market, being widely employed for conditions such as streptococcal infections and rheumatic fever. The broad applicability and proven efficacy of benzathine penicillin-g make it the preferred choice among healthcare providers addressing bacterial diseases. Conversely, the STI treatment segment has emerged with a focus on syphilis, driven by rising infection rates and more proactive screening practices. This segment is gaining traction as public health priorities shift, and healthcare providers adapt to increased demand for effective STI treatments. As antibiotic resistance becomes a concern, benzathine penicillin-g is positioned well as a reliable option in both dominant and emerging applications. ### By Mode of Injection: Intramuscular Injection (Largest) vs. Intravenous Injection (Fastest-Growing) In the US benzathine penicillin-g market, the distribution of market share between the modes of injection reveals that intramuscular injection holds the largest share due to its established effectiveness and ease of administration. This mode has been widely adopted in clinical settings, making it a preferred choice among healthcare providers. Intravenous injection, while trailing in overall share, is growing rapidly as it offers advantages in terms of faster therapeutic effects, attracting more attention from the market. Growth trends in this segment are influenced by the increasing prevalence of infectious diseases, which drives the demand for effective antibiotic treatments. The shift towards intravenous injection is particularly pronounced in cases requiring immediate action, while intramuscular injection remains dominant for general use. The ongoing research and development efforts to enhance injection formulations may further bolster the market, encouraging wider adoption across healthcare facilities. Injection Mode: Intramuscular (Dominant) vs. Intravenous (Emerging) Intramuscular injection is characterized by its high patient compliance and established protocols within the US benzathine penicillin-g market, cementing its dominance. It allows for a gradual release of the medication, resulting in sustained therapeutic levels, which is beneficial for many infections. Conversely, intravenous injection is emerging rapidly due to its capability to deliver medications directly into the bloodstream, providing immediate effects that are crucial for severe cases. This flexibility in administration routes caters to a broader patient demographic, enhancing treatment options for healthcare professionals. As the focus on improving patient outcomes continues to grow, both methods are likely to coexist, catering to different clinical needs. ### By End User: Hospitals and clinics (Largest) vs. Ambulatory surgical centers (Fastest-Growing) In the US benzathine penicillin-g market, hospitals and clinics represent the largest segment, accounting for a significant portion of the market. This segment benefits from a well-established infrastructure, a steady flow of patients requiring treatment, and strong relationships with pharmaceutical providers. Ambulatory surgical centers, while smaller in size, are experiencing rapid growth as they become more integrated into patient care pathways and offer cost-effective alternatives to traditional hospital stays. The growth trends in this segment are driven by an increasing prevalence of bacterial infections and a rising demand for effective treatment options. The shift towards outpatient care models is propelling the expansion of ambulatory surgical centers, attracting investment in facilities that provide specialized care. Additionally, innovations in drug formulations and delivery methods play a crucial role in enhancing accessibility and effectiveness, which is vital for driving market growth within this segment. Hospitals and clinics (Dominant) vs. Ambulatory surgical centers (Emerging) The hospitals and clinics segment is characterized by its strong market presence and extensive utilization of benzathine penicillin-g for treating serious infections. These facilities are equipped with advanced medical technologies and staffed by experienced healthcare professionals, ensuring high-quality patient care. Their dominant position is supported by long-term contracts with pharmaceutical companies and reimbursement policies that favor hospital settings. In contrast, ambulatory surgical centers are emerging as a vital part of the healthcare ecosystem, appealing to patients seeking convenience and lower costs. These centers focus on outpatient procedures, and their growth is bolstered by an increasing patient preference for receiving care outside hospital environments. As the healthcare industry evolves, both segments will continue to play critical roles in the distribution and application of benzathine penicillin-g. ## Competitive Benchmarking The benzathine penicillin-g market is characterized by a competitive landscape that is increasingly shaped by innovation, strategic partnerships, and regional expansion. Key players such as Bristol-Myers Squibb (US), Boehringer Ingelheim (DE), and Pfizer (US) are actively pursuing strategies that enhance their market positioning. Bristol-Myers Squibb (US) has focused on expanding its product portfolio through research and development, while Boehringer Ingelheim (DE) emphasizes sustainable practices in its manufacturing processes. Pfizer (US) is leveraging its extensive distribution network to enhance accessibility, thereby influencing the competitive dynamics of the market.In terms of business tactics, companies are localizing manufacturing to reduce costs and optimize supply chains. The market appears moderately fragmented, with several players vying for market share. This fragmentation allows for a diverse range of products and pricing strategies, which collectively influence the competitive environment. The presence of both large multinational corporations and smaller firms creates a dynamic interplay that drives innovation and responsiveness to market demands. In October Bristol-Myers Squibb (US) announced a strategic partnership with a leading biotechnology firm to enhance its research capabilities in antibiotic development. This collaboration is expected to accelerate the introduction of novel formulations of benzathine penicillin-g, thereby strengthening its competitive edge. The strategic importance of this partnership lies in its potential to address emerging antibiotic resistance, a growing concern in the healthcare sector. In September Pfizer (US) launched a new initiative aimed at improving the supply chain efficiency of benzathine penicillin-g. This initiative includes the implementation of advanced analytics and AI-driven logistics solutions. The strategic significance of this move is underscored by the need for reliable supply chains, particularly in the context of increasing demand for antibiotics. By enhancing its operational efficiency, Pfizer (US) positions itself favorably against competitors. In August Boehringer Ingelheim (DE) unveiled a sustainability program focused on reducing the environmental impact of its manufacturing processes. This initiative not only aligns with global sustainability trends but also enhances the company's reputation among environmentally conscious consumers. The strategic importance of this program is evident as it may lead to cost savings and improved regulatory compliance, thereby strengthening Boehringer Ingelheim's market position. As of November the competitive trends in the benzathine penicillin-g market are increasingly defined by digitalization, sustainability, and the integration of AI technologies. Strategic alliances are becoming more prevalent, as companies recognize the value of collaboration in driving innovation. The competitive landscape is likely to evolve from a focus on price-based competition to one that prioritizes technological advancements, supply chain reliability, and sustainable practices. This shift suggests that companies that can effectively differentiate themselves through innovation and operational excellence will be better positioned for future success. ## Recent News & Developments The US Benzathine Penicillin G Market has seen significant activity recently, reflecting ongoing dynamics among key players such as Bristol Myers Squibb, AstraZeneca, Novartis, Merck, Par Pharmaceutical, Sandoz, Pfizer, Amgen, Stella Pharma, Hikma Pharmaceuticals, Eurand, GSK, Mylan, Teva Pharmaceuticals, and Sun Pharmaceutical. In August 2023, Pfizer announced a collaboration with a biotechnology firm to enhance its manufacturing capabilities, which could impact the supply chain positively. Additionally, the market valuation for Benzathine Penicillin G has experienced growth, with a reported increase in demand due to rising cases of bacterial infections, contributing to expansion for companies like Merck and Hikma Pharmaceuticals. The past two years have witnessed notable regulatory developments, with the FDA prioritizing support for generic versions to improve access. Notably, in April 2022, AstraZeneca expanded its production facility in the US specifically targeting antibiotics, including Benzathine Penicillin G, illustrating a strategic effort to bolster its market presence while addressing public health needs. This combination of partnerships, government collaboration, and product focus indicates a robust and evolving market landscape in the US for Benzathine Penicillin G. ## Report Scope | MARKET SIZE 2024 | 0.301(USD Million) | | --- | --- | | MARKET SIZE 2025 | 0.326(USD Million) | | MARKET SIZE 2035 | 0.725(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 8.33% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Bristol-Myers Squibb (US), Boehringer Ingelheim (DE), Sandoz (CH), Mylan (US), Teva Pharmaceuticals (IL), Pfizer (US), Aurobindo Pharma (IN), Hikma Pharmaceuticals (GB) | | Segments Covered | Application, Mode of Injection, End User | | Key Market Opportunities | Growing demand for benzathine penicillin-g in treating rheumatic heart disease presents a market opportunity. | | Key Market Dynamics | Regulatory changes and competitive pressures drive innovation in the benzathine penicillin-g market. | | Countries Covered | US | ## Frequently Asked Questions **Q: What was the market valuation of benzathine penicillin-g in 2024?** A: The market valuation of benzathine penicillin-g was $0.301 Million in 2024. **Q: What is the projected market valuation for benzathine penicillin-g by 2035?** A: The projected market valuation for benzathine penicillin-g is $0.725 Million by 2035. **Q: What is the expected CAGR for the US benzathine penicillin-g market during 2025 - 2035?** A: The expected CAGR for the US benzathine penicillin-g market during 2025 - 2035 is 8.33%. **Q: Which companies are the key players in the benzathine penicillin-g market?** A: Key players in the benzathine penicillin-g market include Bristol-Myers Squibb, Boehringer Ingelheim, Sandoz, Mylan, Teva Pharmaceuticals, Pfizer, Aurobindo Pharma, and Hikma Pharmaceuticals. **Q: What are the main applications of benzathine penicillin-g?** A: The main applications of benzathine penicillin-g include treatment for bacterial infections and sexually transmitted infections, particularly syphilis. **Q: What was the market size for bacterial infections in 2024?** A: The market size for bacterial infections was $0.18 Million in 2024. **Q: What is the projected market size for the treatment of syphilis by 2035?** A: The projected market size for the treatment of syphilis is $0.305 Million by 2035. **Q: What modes of injection are used for benzathine penicillin-g?** A: The modes of injection for benzathine penicillin-g include intravenous and intramuscular injections. **Q: What was the market size for intramuscular injection in 2024?** A: The market size for intramuscular injection was $0.226 Million in 2024. **Q: Which end users are primarily involved in the benzathine penicillin-g market?** A: Primary end users in the benzathine penicillin-g market include hospitals, clinics, ambulatory surgical centers, diagnostic centers, and research centers. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-benzathine-penicillin-g-market-18939*